Kintor Pharmaceutical

  • Land: Hong Kong

Nachricht vom 17.06.2021 | 11:17

Proxalutamide's Pivotal Study of Treating COVID-19 Male Outpatients Sponsored by Kintor was Approved by ANVISA and CONEP in Brazil


EQS-News / 17/06/2021 / 17:17 UTC+8

Proxalutamide's Pivotal Study of Treating COVID-19 Male Outpatients Sponsored by Kintor was Approved by ANVISA and CONEP in Brazil

 

 

Suzhou, June 15, 2021 - Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved the phase III clinical trial of proxalutamide to treat male patients with mild or moderate COVID-19 symptoms on June 11, 2021[1]. The pivotal phase III study was approved by the Brazilian National Research and Ethics Committee (CONEP) on May 27, 2021[2].

 

The phase III trial (NCT04869228) is a randomized, double-blind, placebo-controlled, multi-regional study, designed to evaluate the efficacy and safety of proxalutamide in male patients with mild or moderate COVID-19 symptoms. The primary endpoint for the trial is the percentage of subjects requiring oxygen by day 28. Kintor expects the first patient dosing for the trial to commence in July 2021.

 

The Brazilian study is the third pivotal study of proxalutamide in the treatment of COVID-19 sponsored by Kintor. The Brazilian approval came along with the U.S. Food and Drug Administration's (FDA) clearance of two pivotal trials studying proxalutamide's treatment of U.S. COVID-19 outpatients and inpatients.


 

Dr. Tong Youzhi, the founder, Chairman, and CEO of Kintor Pharmaceutical, commented, "We are delighted to receive the approval from ANVISA and CONEP for this Brazilian phase III clinical trial of proxalutamide in COVID-19 patients. Once the previously reported results of the investigator-initiated trial (IIT) in Brazil became available, Kintor itself filed a pre-IND application with ANVISA as part of a multi-regional clinical trial. We look forward to continuing our positive relationship with the Brazilan regulators and expect this approval will pave the way for Kintor to apply for an emergency use authorization (EUA) and the eventual commercialization of proxalutamide for the treatment of COVID-19 in Brazil."

 

About Proxalutamide (GT-0918)

 

Proxalutamide is a nonsteroidal antiandrogen -specifically, a selective high-affinity silent antagonist of the androgen receptor - that is under development for the potential treatment of COVID-19, prostate cancer, and breast cancer.

 

About Kintor Pharmaceutical Limited

 

Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancer, alopecia and acne. For more information, visit www.kintor.com.cn.

 

[1] ANVISA :https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/pesquisaclinica/arquivos/ensaios-clinicos-covid.pdf/view

[2] CONEP CAAE: 46013221.7.1001.5412; Opinion Number: 4,737,494

 

17/06/2021 Dissemination of a Marketing Press Release, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

show this

IPO im Fokus

MIT SICHERHEIT AUFS PARKETT. UNSER BÖRSENGANG ZUR WACHSTUMSBESCHLEUNIGUNG

ISIN: DE000A3CM708
Grundkapital (vor IPO): 3.120.000 EUR
Angebotene Aktien: bis zu 690.000 Aktien
Zeichnungsfrist: 11.10.2021 bis voraus. 25.10.2021
Bookbuildingspanne: 3,30 bis 3,60 Euro
Börse: Börse Düsseldorf

Rechtlich maßgeblicher Wertpapierprospekt auf sdm-se.de

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

IIF – International Investment Forum

Wann: 14. Oktober 2021, 9:45 - 18:00 Uhr
Wo: Online Live-Event via ZOOM
Wer: börsennotierte Unternehmen aus den Small- und Midcap-Segmenten aller Welt
Branchen: Technologie, Rohstoffe, Sicherheit, Medizin, Logistik und Raumfahrt
Für: Alle Investoren & Presse
Weitere Informationen: www.ii-forum.com

News im Fokus

Delivery Hero verstärkt seine Präsenz in Zentralamerika und der Karibik durch die Übernahme der Restaurant- und Lebensmittellieferdienste von hugo

14. Oktober 2021, 08:00

Aktuelle Research-Studie

2G Energy AG

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Hinzufügen

15. Oktober 2021